Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy

December 18, 2013 updated by: University of Sao Paulo
Orbital Venous flow study in patients with Grave's Orbitopathy in different manifestation forms and stages, made with Color Doppler Imaging

Study Overview

Status

Completed

Detailed Description

Prospective study with Grave's patients in active and fibrotic disease, myogenic and lipogenic forms, with muscle restriction and without muscle restriction and with or without optic compressive neuropathy. Blood flow was studied with Color Doppler Imaging (CDI) in the following orbital vessels:

  • Superior Ophthalmic Vein (main target of the study protocol)
  • Retinal Central Vein
  • Retinal Central Artery
  • Ophthalmic Artery

Study Type

Observational

Enrollment (Actual)

66

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • São Paulo, Brazil, 05403-000
        • Hospital das Clínicas da Universidade São Paulo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with Grave's disease within the orbital service of HCFMUSP at the Ophthalmology Department

Description

Inclusion Criteria:

  • Clinical diagnosis of Grave's Orbitopathy with well defined disease.

Exclusion Criteria:

  • Uncertain cases, with an undefined status of Grave's Ophthalmopathy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group control with healthy subjects
Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
Graves' Ophthalmopathy - fibrotic phase
Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
Graves' Ophthalmopathy - active phase
Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Mário LR Monteiro, Professor, Instituto do Coracao
  • Study Chair: Joseph E Benabou, Instituto do Coracao

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2007

Primary Completion (Actual)

December 1, 2008

Study Completion (Actual)

December 1, 2008

Study Registration Dates

First Submitted

June 11, 2008

First Submitted That Met QC Criteria

June 13, 2008

First Posted (Estimate)

June 16, 2008

Study Record Updates

Last Update Posted (Estimate)

December 19, 2013

Last Update Submitted That Met QC Criteria

December 18, 2013

Last Verified

June 1, 2008

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Graves' Ophthalmopathy

3
Subscribe